Human herpesvirus 6B (HHV-6B) is the etiologic agent of exanthem subitum, a common febrile illness in infants and young children. 1 Like other human herpesviruses, the virus remains latent in hosts after primary HHV-6B infection and reactivates in immunocompromised patients, including hematopoietic stem cell transplant (HSCT) recipients. On the basis of in vitro and in vivo investigations, HHV-6B is thought to have neurovirulence. 2, 3 Our recent data suggested that the pathogenesis and clinical features of HHV-6B encephalitis are different in patients with primary infection and HSCT recipients with viral reactivation. 4 Various types of clinical manifestations including acute encephalopathy with biphasic seizures and late reduced diffusion, acute necrotizing encephalopathy and hemorragic shock and encephalopathy syndrome have been reported in patients with primary HHV-6B encephalitis. 5 It is also well known that HHV-6B is the most important pathogen in post-transplant acute limbic encephalitis. 6 Posterior reversible encephalopathy syndrome (PRES) was first reported by Hinchey et al. 7 as a syndrome of headaches, confusion, seizures and visual disturbances associated with transient, predominantly posterior white matter changes on neuroimaging studies. PRES has been associated with a number of medical conditions, including hypertensive encephalopathy, eclampsia, and the use of cytotoxic and immunosuppressive drugs. PRES is also seen in solid organ transplant recipients and HSCT recipients. Although several infectious agents are thought to be involved in its pathophysiology, 8 no cases of PRES associated with HHV-6B have been reported to date. Herein, we report the first case of PRES with HHV-6B reactivation after HSCT.
An 11-year-old Japanese boy who was seropositive for HHV-6B underwent mismatched unrelated donor BM transplant for relapsed ALL. The conditioning regimen included TRI (12 Gy) and melphalan (180 mg/m 2 ). Tacrolimus was administered initially as 0.02 mg/kg i.v. daily, starting 1 day before transplant. MTX was administered on day 1 (15 mg/m 2 of body surface area), and day 3, 6 and 11 (10 mg/m 2 ) post-transplant for GVHD prophylaxis. The patient had fever and rash on day 7 and was given methylprednisolone 2 mg/kg daily starting on day 9 for engraftment syndrome. The fever and rash promptly resolved. On day 20 he developed a high fever and a generalized clonic seizure. Subsequently, he also developed stupor, confusion and disorientation. No other abnormal findings were observed on neurological examinations. Blood pressure ranged from 130 to 170/70 to 90 mmHg. Hematological examinations revealed mild thrombocytopenia (85 000/mL). The serum concentration of tacrolimus was within target limits (6.1 ng/mL). Additionally, cerebrospinal fluid (CSF) collected on day 24 post-transplant showed increased protein (42 mg/dL) and no pleocytosis. T2-weighted and fluid-attenuated inversion recovery magnetic resonance imaging on day 22 post-transplant showed highintensity areas in both cerebellar hemispheres and the left occipital lobe (Figure 1 ). The patient was diagnosed with PRES based on clinical and neuroimaging findings. He was treated with a calcium channel blocker to lower blood pressure starting on day 22 post transplant.
Neither bacteria nor fungus was isolated from the patient. Realtime PCR (RT--PCR) did not detect CMV DNA in the serum. However, as high levels of HHV-6B DNA were detected in the patient's serum (29 600 copies/mL; day 17 post transplant) and CSF (311 000 copies/mL, day 24 post transplant), HHV-6B was thought to be associated with PRES. Therefore, ganciclovir was initiated on day 24 post transplant, with gradual improvement in his neurological symptoms. Although his neurological symptoms resolved completely, the patient died on day 105 post transplant due to GVHD. In order to elucidate the pathophysiology of HHV-6B-associated PRES, the kinetics of viral DNA and biomarkers in serially collected serum and CSF samples were analyzed. HHV-6B DNA copy number was measured by RT-PCR, and six biomarkers were measured by the Cytometric Bead Array system (BD Biosciences, San Jose, CA, USA). As shown in Table 1 , high copy numbers of HHV-6B DNA were detected in the serum starting 3 days before the onset of neurological symptoms, and HHV-6B DNA decreased to undetectable levels in the serum, whereas high copy numbers of HHV-6B DNA were detected in the CSF on day 24 post transplant. Serum levels of three inflammatory cytokines (IL-1b, IL-6, and TNF-a) and IL-8 were increased in the serum sample collected after onset of PRES. Although IL-1b concentrations were similar in the serum and CSF on day 24 post-transplant, no obvious increases in other biomarkers were observed in the CSF.
On the basis of the typical clinical course and neuroimaging findings, the patient was diagnosed with PRES. Although the precise mechanism of PRES remains unclear, hypertension and immunosuppressive drugs such as tacrolimus have been proposed as risk factors. 9 As the patient had hypertension and received tacrolimus, these two factors might have important roles in the pathogenesis of PRES. In addition, systemic and central nervous system (CNS) reactivation of HHV-6B occurred concurrently with the onset of PRES. Furthermore, ganciclovir, which has antiviral activity against HHV-6B, in combination with a calcium channel blocker, appeared to be effective in resolving the patient's neurological symptoms. Thus, these present findings strongly suggest that HHV-6B might be a new infectious agent associated with PRES. To our knowledge, this is the first patient with PRES associated with HHV-6B reactivation after HSCT. It has been suggested that post-transplant HHV-6B encephalitis generally manifests as limbic encephalitis. 2 Among HSCT recipients, patients with limbic encephalitis and PRES should be checked for HHV-6B infection.
Although it is difficult to determine the precise role of HHV-6B in the pathogenesis of PRES based on one case, the virological and biomarkers analysis provides interesting observations. Systemic HHV-6B reactivation preceding the onset of neurological symptoms and followed by up-regulation of inflammatory cytokines and IL-8 may be a trigger for vasogenic edema in the brain. Moreover, although HHV-6B reactivation occurred in the CNS during the acute phase, no obvious upregulation of cytokines except for IL-1b was seen in the CSF. Thus, it is likely that antiviral drugs that inhibit HHV-6B reactivation in the CNS are more useful than anti-cytokine treatments for treating PRES. Although this patient had a complete recovery from PRES, severe neurological sequelae have been reported in some PRES patients. 10 Thus, the development of reliable treatment strategies for HHV-6B-associated PRES is necessary to improve prognosis. Further analysis of a larger number of cases should be carried out to elucidate the precise pathophysiology and the best treatment strategy for HHV-6B-associated PRES. Abbreviations: CSF ¼ cerebrospinal fluid; HHV-6B ¼ human herpesvirus 6B.
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